Radioisotope company TAG1 Inc. will participate in the Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025, presenting its innovative approach to strengthening the global supply chain for Targeted Alpha Therapies (TATs).
CEO Sumit Verma will speak on a panel titled "Radiopharma Isotope Roadmap: Clinical & Logistical Considerations" alongside executives from Lantheus Holdings and Radiopharm Theranostics. The panel, moderated by JonesTrading's Justin Walsh, will explore critical developments in radiopharmaceutical technologies.
The conference, organized by JonesTrading and marketed by B2i Digital, provides a platform for innovative companies to engage directly with institutional investors through one-on-one meetings, fireside chats, and networking opportunities.
TAG1's participation underscores the growing importance of medical isotopes like Lead-212 in developing next-generation cancer treatments. By providing high-purity isotopes through its proprietary portable generator technology, the company aims to support nuclear radiopharmacies, hospital networks, and research institutions in advancing radioligand therapies.
The conference will also feature keynote addresses from Dr. Charity Dean, CEO of PHC Global, and Eric F. Trump, Executive Vice President of The Trump Organization, adding additional depth to the event's technological and innovation focus.
TAG1's virtual company presentation on April 9 at 3:00 PM will provide further insights into the company's strategic approach to improving radiopharmaceutical supply chains and supporting critical cancer treatment research.
